Convergence Investment Partners’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.16M | Sell |
29,860
-13,826
| -32% | -$1.94M | 0.68% | 43 |
|
|
2025
Q4 | $5.36M | Buy |
43,686
+1,217
| +3% | +$148K | 1.07% | 18 |
|
|
2025
Q3 | $4.71M | Sell |
42,469
-12,842
| -23% | -$1.46M | 1.06% | 18 |
|
|
2025
Q2 | $6.13M | Buy |
55,311
+2,119
| +4% | +$226K | 1.55% | 9 |
|
|
2025
Q1 | $5.96M | Sell |
53,192
-15,255
| -22% | -$1.57M | 1.65% | 7 |
|
|
2024
Q4 | $6.32M | Buy |
68,447
+9,330
| +16% | +$840K | 1.41% | 8 |
|
|
2024
Q3 | $4.96M | Buy |
59,117
+8,232
| +16% | +$628K | 1.34% | 13 |
|
|
2024
Q2 | $3.49M | Sell |
50,885
-193
| -0.4% | -$12.9K | 1.02% | 21 |
|
|
2024
Q1 | $3.74M | Buy |
51,078
+5,389
| +12% | +$414K | 1.43% | 11 |
|
|
2023
Q4 | $3.7M | Sell |
45,689
-3,495
| -7% | -$272K | 1.93% | 7 |
|
|
2023
Q3 | $3.69M | Sell |
49,184
-186
| -0.4% | -$14.3K | 2.18% | 6 |
|
|
2023
Q2 | $3.81M | Sell |
49,370
-1,527
| -3% | -$122K | 2.18% | 6 |
|
|
2023
Q1 | $4.22M | Sell |
50,897
-46
| -0.1% | -$3.81K | 2.48% | 5 |
|
|
2022
Q4 | $4.37M | Buy |
50,943
+857
| +2% | +$67.9K | 2.59% | 2 |
|
|
2022
Q3 | $3.09M | Buy |
50,086
+18,540
| +59% | +$1.17M | 2.02% | 6 |
|
|
2022
Q2 | $1.95M | Sell |
31,546
-3,007
| -9% | -$186K | 1.18% | 21 |
|
|
2022
Q1 | $2.05M | Buy |
34,553
+388
| +1% | +$24.8K | 1.06% | 24 |
|
|
2021
Q4 | $2.48M | Buy |
34,165
+934
| +3% | +$64.3K | 1.26% | 18 |
|
|
2021
Q3 | $2.32M | Buy |
33,231
+5,378
| +19% | +$378K | 1.25% | 17 |
|
|
2021
Q2 | $1.92M | Sell |
27,853
-3,991
| -13% | -$266K | 0.82% | 43 |
|
|
2021
Q1 | $2.06M | Buy |
31,844
+76
| +0.2% | +$4.9K | 0.94% | 35 |
|
|
2020
Q4 | $1.85M | Sell |
31,768
-33,152
| -51% | -$2M | 0.93% | 31 |
|
|
2020
Q3 | $4.1M | Sell |
64,920
-2,497
| -4% | -$173K | 1.43% | 9 |
|
|
2020
Q2 | $5.19M | Buy |
67,417
+3,750
| +6% | +$287K | 1.78% | 6 |
|
|
2020
Q1 | $4.76M | Buy |
63,667
+1,424
| +2% | +$98.4K | 2.08% | 5 |
|
|
2019
Q4 | $4.04M | Sell |
62,243
-1,218
| -2% | -$79.3K | 1.15% | 19 |
|
|
2019
Q3 | $4.02M | Buy |
63,461
+31,953
| +101% | +$2.09M | 1.12% | 17 |
|
|
2019
Q2 | $2.13M | Buy |
31,508
+197
| +0.6% | +$13K | 0.51% | 60 |
|
|
2019
Q1 | $2.04M | Buy |
31,311
+141
| +0.5% | +$9.37K | 0.44% | 72 |
|
|
2018
Q4 | $1.95M | Buy |
31,170
+4,870
| +19% | +$340K | 0.45% | 77 |
|
|
2018
Q3 | $2.03M | Buy |
26,300
+7,374
| +39% | +$557K | 0.41% | 86 |
|
|
2018
Q2 | $1.34M | Sell |
18,926
-12,280
| -39% | -$867K | 0.19% | 156 |
|
|
2018
Q1 | $2.35M | Sell |
31,206
-62,852
| -67% | -$5M | 0.31% | 121 |
|
|
2017
Q4 | $6.74M | Buy |
94,058
+26
| +0% | +$1.97K | 0.9% | 14 |
|
|
2017
Q3 | $7.62M | Buy |
94,032
+38,172
| +68% | +$2.92M | 1.08% | 8 |
|
|
2017
Q2 | $3.95M | Sell |
55,860
-44,196
| -44% | -$2.94M | 0.58% | 37 |
|
|
2017
Q1 | $6.8M | Buy |
100,056
+39,451
| +65% | +$2.77M | 0.95% | 10 |
|
|
2016
Q4 | $4.34M | Buy |
60,605
+18,051
| +42% | +$1.34M | 0.6% | 36 |
|
|
2016
Q3 | $3.37M | Sell |
42,554
-58,696
| -58% | -$4.77M | 0.5% | 56 |
|
|
2016
Q2 | $8.45M | Sell |
101,250
-19,551
| -16% | -$1.74M | 1.16% | 7 |
|
|
2016
Q1 | $11.1M | Sell |
120,801
-6,650
| -5% | -$600K | 1.32% | 3 |
|
|
2015
Q4 | $12.9M | Buy |
127,451
+139
| +0.1% | +$14.5K | 1.45% | 3 |
|
|
2015
Q3 | $12.5M | Sell |
127,312
-938
| -0.7% | -$104K | 1.43% | 5 |
|
|
2015
Q2 | $15M | Buy |
128,250
+56,058
| +78% | +$6.13M | 1.48% | 3 |
|
|
2015
Q1 | $7.08M | Sell |
72,192
-2,606
| -3% | -$265K | 0.98% | 7 |
|
|
2014
Q4 | $7.05M | Sell |
74,798
-3,267
| -4% | -$338K | 0.94% | 11 |
|
|
2014
Q3 | $8.31M | Buy |
+78,065
| New | +$7.64M | 1.14% | 7 |
|
Other funds holding GILD
VCM
VPM
Convergence Investment Partners's GILD Position: Q1 2026 in Review
Convergence Investment Partners reduced its Gilead Sciences (GILD) stake by 32% in Q1 2026, selling an estimated $1.94M and leaving 29,860 shares worth $4.16M. The position accounts for 0.68% of the portfolio, ranked #43.
Convergence Investment Partners first reported a position in GILD in Q3 2014 and has held it in 47 quarters since. The position peaked at $15M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Convergence Investment Partners held 29,860 shares of Gilead Sciences worth $4.16M as of Q1 2026.
- Convergence Investment Partners sold 13,826 Gilead Sciences shares in Q1 2026, an estimated $1.94M.
- Gilead Sciences made up 0.68% of Convergence Investment Partners's portfolio in Q1 2026, its #43 holding.
- Convergence Investment Partners first reported a position in Gilead Sciences in Q3 2014 and has held it in 47 quarters since.
- Convergence Investment Partners's Gilead Sciences position peaked at $15M in Q2 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.